NCT04643678 is a Phase 2, PHASE3 clinical trial of Anakinra in Covid19, sponsored by Hamad Medical Corporation.

Who is sponsoring NCT04643678?

NCT04643678 is sponsored by Hamad Medical Corporation.

What drugs are being tested in NCT04643678?

Interventions in NCT04643678: Anakinra, Standard of Care.

What condition does NCT04643678 study?

NCT04643678 studies Covid19, Pneumonia, Cytokine Release Syndrome, Corona Virus Infection, Viral Infection.

Is NCT04643678 still recruiting?

NCT04643678 is currently completed. Last updated 16 August 2022.

Last reviewed 2022-08-16 · How we verify

NCT04643678

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anakinra in the Management of COVID-19 Infection

Completed Phase 2, PHASE3 Last updated 16 August 2022

What this trial tests

Phase 2, PHASE3 trial testing Anakinra in Covid19 in 80 participants. Completed in 30 April 2021.

Timeline

30 October 2020

Primary endpoint
1 March 2021

30 April 2021

Quick facts

Lead sponsor	Hamad Medical Corporation
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	30 October 2020
Primary completion	1 March 2021
Estimated completion	30 April 2021
Sites	1 location across Qatar

Drugs / interventions tested

Anakinra (ANAKINRA) — full drug profile →
Standard of Care

Conditions studied

Covid19 — all drugs for Covid19 →
Pneumonia — all drugs for Pneumonia →
Cytokine Release Syndrome — all drugs for Cytokine Release Syndrome →
Corona Virus Infection — all drugs for Corona Virus Infection →

Sponsor

Hamad Medical Corporation — full company profile →

Who can join

18 and older, any sex, with Covid19 or Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronavirus Disease 2019 (COVID-19) was first isolated in Wuhan, China in December 2019. It is rapidly spreading worldwide, posing a severe threat to global health. Many therapeutics have been investigated for the treatment of this disease with inconclusive outcomes. Anakinra - an interleukin (IL)-1 receptor antagonist - had showed survival benefits in patients with macrophage activation syndrome (MAS) and sepsis and was investigated for the use in COVID-19 infection with promising outcomes.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B, Chan L, Knapp JP, Karimi N, et al · · 2021 · cited 41× · PMID 34359931 · DOI 10.3390/cells10071761
NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments.
Gillot C, Favresse J, Mullier F, Lecompte T, et al · · 2021 · cited 39× · PMID 34421600 · DOI 10.3389/fphar.2021.708302
NLRP3 inflammasome activation in COVID-19: an interlink between risk factors and disease severity.
Amin S, Aktar S, Rahman MM, Chowdhury MMH. · · 2022 · cited 37× · PMID 34838941 · DOI 10.1016/j.micinf.2021.104913
Interleukin-1 blocking agents for treating COVID-19.
Davidson M, Menon S, Chaimani A, Evrenoglou T, et al · · 2022 · cited 33× · PMID 35080773 · DOI 10.1002/14651858.cd015308
IL-6 modulation for COVID-19: the right patients at the right time?
Ascierto PA, Fu B, Wei H. · · 2021 · cited 33× · PMID 33837054 · DOI 10.1136/jitc-2020-002285
Current evidence on the use of anakinra in COVID-19.
Khani E, Shahrabi M, Rezaei H, Pourkarim F, et al · · 2022 · cited 31× · PMID 35905562 · DOI 10.1016/j.intimp.2022.109075
Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches.
Mahboubi Mehrabani M, Karvandi MS, Maafi P, Doroudian M. · · 2022 · cited 29× · PMID 35138001 · DOI 10.1002/rmv.2334

Verify or expand the search:

Other trials of Anakinra

Trials testing the same drug.

NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07281027 — COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" · Phase 3 · not yet recruiting
NCT07191444 — A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease · recruiting
NCT06666335 — A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF · Phase 4 · not yet recruiting
NCT06697431 — Non Inferiority KawasakI Trial With Anakinra · Phase 4 · not yet recruiting

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Hamad Medical Corporation trials

Trials by the same sponsor.

NCT07333209 — Scheduled Positioning With a Peanutball(SPP) on Labor Outcomes Among Primiparous Women Under Epidural Analgesia · NA · recruiting
NCT07270939 — Optimizing Enteral Nutrition Regimen for Critically Ill Patients · NA · not yet recruiting
NCT07307508 — Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Ra · NA · recruiting
NCT06622577 — The Effect of Dietary Management and Cysteine Supplementation on Growth Parameters and Biochemical Control for Pediatric · NA · not yet recruiting
NCT06887855 — Enhancing Post-Stroke Dysphagia Rehabilitation · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04643678 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hamad Medical Corporation
Last refreshed: 16 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04643678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing